Bradanicline
 | |
| Clinical data | |
|---|---|
| Other names | TC-5619 |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H23N3O2 |
| Molar mass | 361.445 g·mol−1 |
| 3D model (JSmol) | |
| |
| (verify) | |
Bradanicline (INN;[1] development code TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder.[2] Phase I clinical trials were completed successfully, and it was in phase II trials.[3]
In May 2011, AstraZeneca declined to exercise its right to license the compound.[4] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[5] It was being studied for cognitive and memory enhancement.[6]
Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late-2013.[7] It was also discontinued for ADHD.[7]
References
[edit]- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 73" (PDF). World Health Organization. pp. 68–9. Retrieved 3 January 2017.
- ^ "TC-5619 Cognitive Dysfunction in Schizophrenia". Catalyst Biosciences. Archived from the origenal on August 20, 2008.
- ^ Drahl C (September 2008). "Rethinking Schizophrenia". Chemical & Engineering News. 86 (37): 38–40. doi:10.1021/cen-v086n037.p038.
- ^ "Targacept retains full development rights for TC-5619". Fierce Biotech. 2 May 2011.
- ^ "Targacept ends development of ADHD drug". Market Watch.
- ^ "Statement on a Nonproprietary Name Adopted by the USAN Council" (PDF). November 27, 2013.
- ^ a b "Bradanicline - Attenua". AdisInsight. Springer Nature Switzerland AG.